Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022

Haichao ZHAO; Qiang GAO

doi:10.19401/j.cnki.1007-3639.2023.04.002

您当前的位置：

首页 >

文章列表页 >

Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022

Specialists' Commentary | 更新时间：2025-12-31

- Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022
- China Oncology Vol. 33, Issue 4, Pages: 315-326(2023)
- 作者机构：
  
  复旦大学附属中山医院，复旦大学肝癌研究所，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.04.002
  CLC： R735.7
- Received：15 February 2023，
  
  Revised：2023-03-29，
  
  Published：30 April 2023
- 稿件说明：
移动端阅览
Haichao ZHAO, Qiang GAO. Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022[J]. China Oncology, 2023, 33(4): 315-326.
DOI：

Haichao ZHAO, Qiang GAO. Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022[J]. China Oncology, 2023, 33(4): 315-326. DOI： 10.19401/j.cnki.1007-3639.2023.04.002.

摘要

肝癌是发病率和死亡率极高的消化系统恶性肿瘤。近年来，中国肝癌规范化诊疗水平不断提升。单细胞测序、空间组学测序和基于深度学习的人工智能等多种新技术应用使得肝癌基础研究领域不断取得突破，相关创新研究日新月异，对肝癌生物学特性更加全面系统的了解有益于带动产学研和临床疗效的一系列突破，成为提高肝癌治疗效果的关键。随着FOLFOX-HAIC、LEAP-002和KEYNOTE-301等多项大规模前瞻性临床研究结果的公布，为术后和一线治疗失败的肝癌提供了更多的可能。局部治疗和全身系统治疗方案的推陈出新，新的转化研究（TALENTop和IBI305）进一步将中晚期肝癌转化为外科可切除的肝癌，使更多的肝癌患者有机会得到救治。本文就2022年度肝癌领域的基础和临床研究进展予以综述。

Abstract

Hepatocellular carcinoma (HCC) is a malignant digestive tract tumor with extremely high morbidity and mortality. In recent years

diagnosis and treatment of HCC have made significant improvements in China. New technologies such as single-cell sequencing

spatial-omics sequencing and deep learning-based artificial intelligence have led to breakthroughs in basic research of liver cancer. A more comprehensive understanding of the biological characteristics of HCC will push the breakthroughs in industry-university-research and clinical treatment and become the key to improving the treatment efficacy of HCC. With the publication of the results of several large-scale prospective clinical studies such as FOLFOX-HAIC

LEAP-002 and KEYNOTE-301

more possibilities for postoperative HCC and HCC patients with failure of first-line treatment have been opened up. Pushing the boundaries of local and systemic treatment options

new translational studies (TALENTop and IBI305) have further transformed intermediate to advanced hepatocellular carcinoma into surgically resectable disease

giving more patients with HCC the opportunity to be saved. This article summarized the basic and clinical research progress in the field of HCC in 2022.

关键词

Keywords

references

LLOVET J M , KELLEY R K , VILLANUEVA A , et al . Hepatocellular carcinoma [J ] . Nat Rev Dis Primers , 2021 , 7 ( 1 ): 6 . DOI: 10.1038/s41572-020-00240-3 http://doi.org/10.1038/s41572-020-00240-3

MARQUARDT J U , ANDERSEN J B , THORGEIRSSON S S . Functional and genetic deconstruction of the cellular origin in liver cancer [J ] . Nat Rev Cancer , 2015 , 15 ( 11 ): 653 - 667 . DOI: 10.1038/nrc4017 http://doi.org/10.1038/nrc4017

CHEN W , ZHENG R , BAADE P D , et al . Cancer statistics in China, 2015 [J ] . CA Cancer J Clin , 2016 , 66 ( 2 ): 115 - 132 . DOI: 10.3322/caac.21338 http://doi.org/10.3322/caac.21338 http://doi.wiley.com/10.3322/caac.21338 http://doi.wiley.com/10.3322/caac.21338

PEISELER M , SCHWABE R , HAMPE J , et al . Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease-novel insights into cellular communication circuits [J ] . J Hepatol , 2022 , 77 ( 4 ): 1136 - 1160 . DOI: 10.1016/j.jhep.2022.06.012 http://doi.org/10.1016/j.jhep.2022.06.012 https://linkinghub.elsevier.com/retrieve/pii/S0168827822003750 https://linkinghub.elsevier.com/retrieve/pii/S0168827822003750

IOANNOU G N . Epidemiology and risk-stratification of NAFLD-associated HCC [J ] . J Hepatol , 2021 , 75 ( 6 ): 1476 - 1484 . DOI: 10.1016/j.jhep.2021.08.012 http://doi.org/10.1016/j.jhep.2021.08.012

CHEN W , WEN L , BAO Y Y , et al . Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2 [J ] . Proc Natl Acad Sci U S A , 2022 , 119 ( 52 ): e2203894119.

YIP T C , WONG V W , LAI M S , et al . Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss [J ] . J Hepatol , 2023 , 78 ( 3 ): 524 - 533 . DOI: 10.1016/j.jhep.2022.11.020 http://doi.org/10.1016/j.jhep.2022.11.020 https://linkinghub.elsevier.com/retrieve/pii/S0168827822033141 https://linkinghub.elsevier.com/retrieve/pii/S0168827822033141

JOHNSON P , ZHOU Q , DAO D Y , et al . Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma [J ] . Nat Rev Gastroenterol Hepatol , 2022 , 19 ( 10 ): 670 - 681 . DOI: 10.1038/s41575-022-00620-y http://doi.org/10.1038/s41575-022-00620-y

GAO Q , ZENG Q , WANG Z J , et al . Circulating cell-free DNA for cancer early detection [J ] . Innovation (Camb) , 2022 , 3 ( 4 ): 100259 .

YANG X R , LIU R , ZHOU J , et al . Discovery and clinical validation of cost-effective noninvasive early detection of hepatocellular carcinoma (HCC) through circulating tumor DNA (ctDNA) methylation signature [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 4103 . DOI: 10.1200/JCO.2022.40.16_suppl.4103 http://doi.org/10.1200/JCO.2022.40.16_suppl.4103 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4103 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4103

CHEN L , ABOU-ALFA G K , ZHENG B , et al . Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients [J ] . Cell Res , 2021 , 31 ( 5 ): 589 - 592 . DOI: 10.1038/s41422-020-00457-7 http://doi.org/10.1038/s41422-020-00457-7

FODA Z H , ANNAPRAGADA A V , BOYAPATI K , et al . Detecting liver cancer using cell-free DNA fragmentomes [J ] . Cancer Discov , 2023 , 13 ( 3 ): 616 - 631 . DOI: 10.1158/2159-8290.CD-22-0659 http://doi.org/10.1158/2159-8290.CD-22-0659 https://aacrjournals.org/cancerdiscovery/article/13/3/616/716762/Detecting-Liver-Cancer-Using-Cell-Free-DNA https://aacrjournals.org/cancerdiscovery/article/13/3/616/716762/Detecting-Liver-Cancer-Using-Cell-Free-DNA

ZHANG X Y , WANG Z , TANG W , et al . Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics [J ] . Hepatology , 2022 , 76 ( 2 ): 317 - 329 . DOI: 10.1002/hep.32308 http://doi.org/10.1002/hep.32308 https://journals.lww.com/10.1002/hep.32308 https://journals.lww.com/10.1002/hep.32308

QU C F , WANG Y T , WANG P , et al . Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy [J ] . Proc Natl Acad Sci U S A , 2019 , 116 ( 13 ): 6308 - 6312 . DOI: 10.1073/pnas.1819799116 http://doi.org/10.1073/pnas.1819799116 https://pnas.org/doi/full/10.1073/pnas.1819799116 https://pnas.org/doi/full/10.1073/pnas.1819799116

CAI J B , CHEN L , ZHANG Z , et al . Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma [J ] . Gut , 2019 , 68 ( 12 ): 2195 - 2205 . DOI: 10.1136/gutjnl-2019-318882 http://doi.org/10.1136/gutjnl-2019-318882

FUJIWARA N , KUBOTA N , CROUCHET E , et al . Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease [J ] . Sci Transl Med , 2022 , 14 ( 650 ): eabo4474 . DOI: 10.1126/scitranslmed.abo4474 http://doi.org/10.1126/scitranslmed.abo4474 https://www.science.org/doi/10.1126/scitranslmed.abo4474 https://www.science.org/doi/10.1126/scitranslmed.abo4474

ANDERSON N M , SIMON M C . The tumor microenvironment [J ] . Curr Biol , 2020 , 30 ( 16 ): R921 - R925 . DOI: 10.1016/j.cub.2020.06.081 http://doi.org/10.1016/j.cub.2020.06.081 https://linkinghub.elsevier.com/retrieve/pii/S0960982220309337 https://linkinghub.elsevier.com/retrieve/pii/S0960982220309337

XUE R D , ZHANG Q M , CAO Q , et al . Liver tumour immune microenvironment subtypes and neutrophil heterogeneity [J ] . Nature , 2022 , 612 ( 7938 ): 141 - 147 . DOI: 10.1038/s41586-022-05400-x http://doi.org/10.1038/s41586-022-05400-x

CHEN S L , HUANG C , LIAO G R , et al . Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences [J ] . Gut , 2023 : gutjnl-gu2022-328428[ Online ahead of print ] .

LU Y M , YANG A Q , QUAN C , et al . A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma [J ] . Nat Commun , 2022 , 13 ( 1 ): 4594 . DOI: 10.1038/s41467-022-32283-3 http://doi.org/10.1038/s41467-022-32283-3

GUO L , YI X F , CHEN L , et al . Single-cell DNA sequencing reveals punctuated and gradual clonal evolution in hepatocellular carcinoma [J ] . Gastroenterology , 2022 , 162 ( 1 ): 238 - 252 . DOI: 10.1053/j.gastro.2021.08.052 http://doi.org/10.1053/j.gastro.2021.08.052 https://linkinghub.elsevier.com/retrieve/pii/S0016508521034715 https://linkinghub.elsevier.com/retrieve/pii/S0016508521034715

BURGESS D J . Spatial transcriptomics coming of age [J ] . Nat Rev Genet , 2019 , 20 ( 6 ): 317 . DOI: 10.1038/s41576-019-0129-z http://doi.org/10.1038/s41576-019-0129-z

WU Y C , CHENG Y F , WANG X D , et al . Spatial omics: navigating to the golden era of cancer research [J ] . Clin Transl Med , 2022 , 12 ( 1 ): e696 . DOI: 10.1002/ctm2.696 http://doi.org/10.1002/ctm2.696

WU R , GUO W B , QIU X Y , et al . Comprehensive analysis of spatial architecture in primary liver cancer [J ] . Sci Adv , 2021 , 7 ( 51 ): eabg3750 . DOI: 10.1126/sciadv.abg3750 http://doi.org/10.1126/sciadv.abg3750 https://www.science.org/doi/10.1126/sciadv.abg3750 https://www.science.org/doi/10.1126/sciadv.abg3750

LIU Y , XUN Z Z , MA K , et al . Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy [J ] . J Hepatol , 2023 , 78 ( 4 ): 770 - 782 . DOI: 10.1016/j.jhep.2023.01.011 http://doi.org/10.1016/j.jhep.2023.01.011 https://linkinghub.elsevier.com/retrieve/pii/S0168827823000235 https://linkinghub.elsevier.com/retrieve/pii/S0168827823000235

LI Q , NI Y , ZHANG L R , et al . HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation [J ] . Signal Transduct Target Ther , 2021 , 6 ( 1 ): 76 .

XU W , ZHAO Z Y , AN Q M , et al . Comprehensive comparison of patient-derived xenograft models in Hepatocellular Carcinoma and metastatic Liver Cancer [J ] . Int J Med Sci , 2020 , 17 ( 18 ): 3073 - 3081 . DOI: 10.7150/ijms.46686 http://doi.org/10.7150/ijms.46686

QUINN J J , JONES M G , OKIMOTO R A , et al . Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts [J ] . Science , 2021 , 371 ( 6532 ): eabc1944 . DOI: 10.1126/science.abc1944 http://doi.org/10.1126/science.abc1944 https://www.science.org/doi/10.1126/science.abc1944 https://www.science.org/doi/10.1126/science.abc1944

ZHOU L , YU K H , WONG T L , et al . Lineage tracing and single-cell analysis reveal proliferative Prom1 + tumour-propagating cells and their dynamic cellular transition during liver cancer progression [J ] . Gut , 2022 , 71 ( 8 ): 1656 - 1668 .

YANG D , JONES M G , NARANJO S , et al . Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution [J ] . Cell , 2022 , 185 ( 11 ): 1905 - 1923.e25 . DOI: 10.1016/j.cell.2022.04.015 http://doi.org/10.1016/j.cell.2022.04.015

HE L J , PU W J , LIU X X , et al . Proliferation tracing reveals regional hepatocyte generation in liver homeostasis and repair [J ] . Science , 2021 , 371 ( 6532 ): eabc4346 . DOI: 10.1126/science.abc4346 http://doi.org/10.1126/science.abc4346 https://www.science.org/doi/10.1126/science.abc4346 https://www.science.org/doi/10.1126/science.abc4346

SUN Y F , WU L , ZHONG Y , et al . Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma [J ] . Cell , 2021 , 184 ( 2 ): 404 - 421.e16 . DOI: 10.1016/j.cell.2020.11.041 http://doi.org/10.1016/j.cell.2020.11.041

AGHAYEV T , MAZITOVA A M , FANG J R , et al . IL27 signaling serves as an immunologic checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma [J ] . Cancer Discov , 2022 , 12 ( 8 ): 1960 - 1983 . DOI: 10.1158/2159-8290.CD-20-1628 http://doi.org/10.1158/2159-8290.CD-20-1628 https://aacrjournals.org/cancerdiscovery/article/12/8/1960/707258/IL27-Signaling-Serves-as-an-Immunologic-Checkpoint https://aacrjournals.org/cancerdiscovery/article/12/8/1960/707258/IL27-Signaling-Serves-as-an-Immunologic-Checkpoint

WONG A M , DING X F , WONG A M , et al . Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion [J ] . J Hepatol , 2022 , 77 ( 2 ): 410 - 423 . DOI: 10.1016/j.jhep.2022.03.015 http://doi.org/10.1016/j.jhep.2022.03.015 https://linkinghub.elsevier.com/retrieve/pii/S0168827822001842 https://linkinghub.elsevier.com/retrieve/pii/S0168827822001842

WEI C Y , ZHU M X , ZHANG P F , et al . PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma [J ] . J Hepatol , 2022 , 77 ( 1 ): 163 - 176 . DOI: 10.1016/j.jhep.2022.02.019 http://doi.org/10.1016/j.jhep.2022.02.019 https://linkinghub.elsevier.com/retrieve/pii/S016882782200126X https://linkinghub.elsevier.com/retrieve/pii/S016882782200126X

LIU Q X , LI J X , ZHANG W J , et al . Glycogen accumulation and phase separation drives liver tumor initiation [J ] . Cell , 2021 , 184 ( 22 ): 5559 - 5576.e19 . DOI: 10.1016/j.cell.2021.10.001 http://doi.org/10.1016/j.cell.2021.10.001

HU B , YU M C , MA X L , et al . IFNα potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment [J ] . Cancer Discov , 2022 , 12 ( 7 ): 1718 - 1741 . DOI: 10.1158/2159-8290.CD-21-1022 http://doi.org/10.1158/2159-8290.CD-21-1022 https://aacrjournals.org/cancerdiscovery/article/12/7/1718/705192/IFN-Potentiates-Anti-PD-1-Efficacy-by-Remodeling https://aacrjournals.org/cancerdiscovery/article/12/7/1718/705192/IFN-Potentiates-Anti-PD-1-Efficacy-by-Remodeling

NING Z , GUO X , LIU X L , et al . USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma [J ] . Nat Commun , 2022 , 13 ( 1 ): 2187 . DOI: 10.1038/s41467-022-29846-9 http://doi.org/10.1038/s41467-022-29846-9

BERARDI D E , BOCK-HUGHES A , TERRY A R , et al . Lipid droplet turnover at the lysosome inhibits growth of hepatocellular carcinoma in a BNIP3-dependent manner [J ] . Sci Adv , 2022 , 8 ( 41 ): eabo2510 . DOI: 10.1126/sciadv.abo2510 http://doi.org/10.1126/sciadv.abo2510 https://www.science.org/doi/10.1126/sciadv.abo2510 https://www.science.org/doi/10.1126/sciadv.abo2510

SUN R Q , ZHANG Z Y , BAO R X , et al . Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis [J ] . J Hepatol , 2022 , 77 ( 2 ): 453 - 466 . DOI: 10.1016/j.jhep.2022.02.030 http://doi.org/10.1016/j.jhep.2022.02.030

LIU F Z , TIAN T , ZHANG Z , et al . Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma [J ] . Nat Metab , 2022 , 4 ( 8 ): 1022 - 1040 . DOI: 10.1038/s42255-022-00616-7 http://doi.org/10.1038/s42255-022-00616-7

XU J J , JI L , RUAN Y L , et al . UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma [J ] . Signal Transduct Target Ther , 2021 , 6 ( 1 ): 190 .

GAO C , WANG S W , LU J C , et al . KSR2-14-3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma [J ] . Biomark Res , 2022 , 10 ( 1 ): 25 . DOI: 10.1186/s40364-022-00361-9 http://doi.org/10.1186/s40364-022-00361-9

JIN H J , SHI Y P , LV Y Y , et al . EGFR activation limits the response of liver cancer to lenvatinib [J ] . Nature , 2021 , 595 ( 7869 ): 730 - 734 . DOI: 10.1038/s41586-021-03741-7 http://doi.org/10.1038/s41586-021-03741-7

HU B Y , ZOU T T , QIN W , et al . Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma [J ] . Cancer Res , 2022 , 82 ( 20 ): 3845 - 3857 . DOI: 10.1158/0008-5472.CAN-21-4140 http://doi.org/10.1158/0008-5472.CAN-21-4140

PAN J M , ZHANG M , DONG L Q , et al . Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma [J ] . Autophagy , 2023 , 19 ( 4 ): 1184 - 1198 . DOI: 10.1080/15548627.2022.2117893 http://doi.org/10.1080/15548627.2022.2117893 https://www.tandfonline.com/doi/full/10.1080/15548627.2022.2117893 https://www.tandfonline.com/doi/full/10.1080/15548627.2022.2117893

MOK E H K , LEUNG C O N , ZHOU L , et al . Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma [J ] . Cancer Res , 2022 , 82 ( 17 ): 3102 - 3115 .

CALDERARO J , SERAPHIN T P , LUEDDE T , et al . Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma [J ] . J Hepatol , 2022 , 76 ( 6 ): 1348 - 1361 . DOI: 10.1016/j.jhep.2022.01.014 http://doi.org/10.1016/j.jhep.2022.01.014

LIU B E , ZENG Q Y , HUANG J B , et al . IVIM using convolutional neural networks predicts microvascular invasion in HCC [J ] . Eur Radiol , 2022 , 32 ( 10 ): 7185 - 7195 . DOI: 10.1007/s00330-022-08927-9 http://doi.org/10.1007/s00330-022-08927-9

GAO R T , ZHAO S , AISHANJIANG K , et al . Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data [J ] . J Hematol Oncol , 2021 , 14 ( 1 ): 154 . DOI: 10.1186/s13045-021-01167-2 http://doi.org/10.1186/s13045-021-01167-2

SHI J Y , WANG X D , DING G Y , et al . Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning [J ] . Gut , 2021 , 70 ( 5 ): 951 - 961 . DOI: 10.1136/gutjnl-2020-320930 http://doi.org/10.1136/gutjnl-2020-320930 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-320930 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-320930

REIG M , FORNER A , RIMOLA J , et al . BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update [J ] . J Hepatol , 2022 , 76 ( 3 ): 681 - 693 . DOI: 10.1016/j.jhep.2021.11.018 http://doi.org/10.1016/j.jhep.2021.11.018 https://linkinghub.elsevier.com/retrieve/pii/S0168827821022236 https://linkinghub.elsevier.com/retrieve/pii/S0168827821022236

中华人民共和国国家卫生健康委员会医政医管局 . 原发性肝癌诊疗指南(2022年版) [J ] . 中华肝脏病杂志 , 2022 ( 4 ): 367 - 388 .

Medical Administration Bureau of the National Health Commission of the People's Republic of China . Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition) [J ] . Chin J Hepatol , 2022 ( 4 ): 367 - 388 .

VOGEL A , MEYER T , SAPISOCHIN G , et al . Hepatocellular carcinoma [J ] . Lancet , 2022 , 400 ( 10360 ): 1345 - 1362 . DOI: 10.1016/S0140-6736(22)01200-4 http://doi.org/10.1016/S0140-6736(22)01200-4

DI BENEDETTO F , MAGISTRI P , DI SANDRO S , et al . Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma [J ] . JAMA Surg , 2023 , 158 ( 1 ): 46 - 54 . DOI: 10.1001/jamasurg.2022.5697 http://doi.org/10.1001/jamasurg.2022.5697 https://jamanetwork.com/journals/jamasurgery/fullarticle/2798993 https://jamanetwork.com/journals/jamasurgery/fullarticle/2798993

ZHU P , LIAO W , ZHANG W G , et al . A prospective study using propensity score matching to compare long-term survival outcomes after robotic-assisted, laparoscopic, or open liver resection for patients with BCLC stage 0-a hepatocellular carcinoma [J ] . Ann Surg , 2023 , 277 ( 1 ): e103 - e111 . DOI: 10.1097/SLA.0000000000005380 http://doi.org/10.1097/SLA.0000000000005380 https://journals.lww.com/10.1097/SLA.0000000000005380 https://journals.lww.com/10.1097/SLA.0000000000005380

陈昭硕 , 林科灿 , 刘景丰 . 三维可视化技术在原发性肝癌外科手术中的应用 [J ] . 临床肝胆病杂志 , 2022 , 38 ( 3 ): 505 - 509 .

CHEN Z S , LIN K C , LIU J F . Application of three-dimensional visualization in surgical operation for primary liver cancer [J ] . J Clin Hepatol , 2022 , 38 ( 3 ): 505 - 509 .

TABRIZIAN P , HOLZNER M L , MEHTA N , et al . Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma [J ] . JAMA Surg , 2022 , 157 ( 9 ): 779 - 788 . DOI: 10.1001/jamasurg.2022.2800 http://doi.org/10.1001/jamasurg.2022.2800

FAMULARO S , DONADON M , CIPRIANI F , et al . Hepatectomy versus sorafenib in advanced nonmetastatic hepatocellular carcinoma: a real-life multicentric weighted comparison [J ] . Ann Surg , 2022 , 275 ( 4 ): 743 - 752 . DOI: 10.1097/SLA.0000000000005373 http://doi.org/10.1097/SLA.0000000000005373

PENG Z W , FAN W Z , ZHU B W , et al . Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase Ⅲ, randomized clinical trial (LAUNCH) [J ] . J Clin Oncol , 2023 , 41 ( 1 ): 117 - 127 .

LI Q J , HE M K , CHEN H W , et al . Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Ⅲ trial [J ] . J Clin Oncol , 2022 , 40 ( 2 ): 150 - 160 .

WANG Z , LIU M , ZHANG D Z , et al . Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC [J ] . Hepatology , 2022 , 76 ( 1 ): 66 - 77 . DOI: 10.1002/hep.32323 http://doi.org/10.1002/hep.32323 https://journals.lww.com/10.1002/hep.32323 https://journals.lww.com/10.1002/hep.32323

LIU K W , ZHENG H , SUI X Z , et al . Microwave ablation versus surgical resection for subcapsular hepatocellular carcinoma: a propensity score-matched study of long-term therapeutic outcomes [J ] . Eur Radiol , 2023 , 33 ( 3 ): 1938 - 1948 . DOI: 10.1007/s00330-022-09135-1 http://doi.org/10.1007/s00330-022-09135-1

YU J , CHENG Z G , HAN Z Y , et al . Period-dependent survival benefit of percutaneous microwave ablation for hepatocellular carcinoma: a 12-year real-world, multicentric experience [J ] . Liver Cancer , 2022 , 11 ( 4 ): 341 - 353 . DOI: 10.1159/000522134 http://doi.org/10.1159/000522134

LEE S , KANG T W , SONG K D , et al . Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation [J ] . Ann Surg , 2021 , 273 ( 3 ): 564 - 571 . DOI: 10.1097/SLA.0000000000003268 http://doi.org/10.1097/SLA.0000000000003268 https://journals.lww.com/10.1097/SLA.0000000000003268 https://journals.lww.com/10.1097/SLA.0000000000003268

XIA Y , LI J , LIU G H , et al . Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 2 ): 255 - 263 . DOI: 10.1001/jamaoncol.2019.4477 http://doi.org/10.1001/jamaoncol.2019.4477 https://jamanetwork.com/journals/jamaoncology/fullarticle/2756225 https://jamanetwork.com/journals/jamaoncology/fullarticle/2756225

CHEN S L , ZENG X Z , SU T H , et al . Combinatory local ablation and immunotherapies for hepatocellular carcinoma: rationale, efficacy, and perspective [J ] . Front Immunol , 2022 , 13 : 1033000 . DOI: 10.3389/fimmu.2022.1033000 http://doi.org/10.3389/fimmu.2022.1033000 https://www.frontiersin.org/articles/10.3389/fimmu.2022.1033000/full https://www.frontiersin.org/articles/10.3389/fimmu.2022.1033000/full

CHEN B , WU J X , CHENG S H , et al . Phase 2 study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with HCC [J ] . Hepatology , 2021 , 74 ( 5 ): 2595 - 2604 . DOI: 10.1002/hep.31993 http://doi.org/10.1002/hep.31993 https://journals.lww.com/10.1002/hep.31993 https://journals.lww.com/10.1002/hep.31993

SU K , GU T , XU K , et al . Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study [J ] . Hepatol Int , 2022 , 16 ( 4 ): 858 - 867 . DOI: 10.1007/s12072-022-10339-2 http://doi.org/10.1007/s12072-022-10339-2

DAWSON L A , WINTER K , KNOX J , et al . NRG/RTOG 1112: randomized phase Ⅲ study of sorafenib vs stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) (NCT01730937) [J ] . Int J Radiat Oncol Biol Physics , 2022 , 114 ( 5 ): 1057 . DOI: 10.1016/j.ijrobp.2022.09.002 http://doi.org/10.1016/j.ijrobp.2022.09.002 https://linkinghub.elsevier.com/retrieve/pii/S0360301622032606 https://linkinghub.elsevier.com/retrieve/pii/S0360301622032606

SUN Y K , ZHANG W , BI X Y , et al . Systemic therapy for hepatocellular carcinoma: Chinese consensus-based interdisciplinary expert statements [J ] . Liver Cancer , 2022 , 11 ( 3 ): 192 - 208 . DOI: 10.1159/000521596 http://doi.org/10.1159/000521596

FINN R S . LBA34-primary results from the phase Ⅲ LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) [C ] . ESMO Congress , 2022 : S808 -S869.

QIN S , CHAN L S , GU S , et al . LBA35 Camrelizumab (C) plus rivoceranib (R) vs sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase Ⅲtrial [J ] . Ann Oncol , 2022 , 33 : S1401 - S1402 .

QIN S K , CHEN Z D , FANG W J , et al . Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase Ⅲtrial [J ] . J Clin Oncol , 2023 , 41 ( 7 ): 1434 - 1443 . DOI: 10.1200/JCO.22.00620 http://doi.org/10.1200/JCO.22.00620 https://ascopubs.org/doi/10.1200/JCO.22.00620 https://ascopubs.org/doi/10.1200/JCO.22.00620

SHAO G L , BAI Y X , YUAN X L , et al . Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): a randomised, multicentre, double-blind study [J ] . EClinicalMedicine , 2022 , 54 : 101679 . DOI: 10.1016/j.eclinm.2022.101679 http://doi.org/10.1016/j.eclinm.2022.101679 https://linkinghub.elsevier.com/retrieve/pii/S2589537022004096 https://linkinghub.elsevier.com/retrieve/pii/S2589537022004096

KUDO M . Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma [J ] . Hepatobiliary Surg Nutr , 2022 , 11 ( 4 ): 592 - 596 . DOI: 10.21037/hbsn http://doi.org/10.21037/hbsn http://hbsn.amegroups.com http://hbsn.amegroups.com

XING B , DA X , ZHANG Y , et al . A phase Ⅱ study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): updated efficacy and safety results [J ] . JCO , 2022 , 40 ( 16_suppl ): 4115 . DOI: 10.1200/JCO.2022.40.16_suppl.4115 http://doi.org/10.1200/JCO.2022.40.16_suppl.4115 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4115 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4115

SUN H C , ZHOU J , WANG Z , et al . Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) [J ] . Hepatobiliary Surg Nutr , 2022 , 11 ( 2 ): 227 - 252 . DOI: 10.21037/hbsn http://doi.org/10.21037/hbsn http://hbsn.amegroups.com http://hbsn.amegroups.com

SUN H , ZHU X , GAO Q , et al . Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate stage hepatocellular carcinoma (HCC): a phase Ⅱ trial [J ] . Ann Oncol , 2022 , 33 : S867 - S868 .

SUN H C , SHEN F , LIU L X , et al . TALENTop: a multicenter, randomized study evaluating the efficacy and safety of hepatic resection for selected hepatocellular carcinoma with macrovascular invasion after initial atezolizumab plus bevacizumab treatment [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): TPS4175 . DOI: 10.1200/JCO.2022.40.16_suppl.TPS4175 http://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4175 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS4175 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS4175

SUN H , SHEN F , BAI X , et al . Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: a pre-specified analysis of the TALENTop study [J ] . Ann Oncol , 2022 , 33 ( 1_suppl ): 1470 .

LIU D . Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): a prospective, single-arm phase Ⅱ trial [C ] . 2022 ASCO Annual Meeting I. American Society of Clinical Oncology (ASCO) . 2022 .

FENG X B , ZHANG L , NIU H M , et al . Selective internal radiation therapy with yttrium-90 resin microspheres followed by anatomical hepatectomy: a potential curative strategy in advanced hepatocellular carcinoma [J ] . Asia Pac J Clin Oncol , 2023 [ Online ahead of print ] .

CAI Z X , SU X P , QIU L M , et al . Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion [J ] . Mol Cancer , 2021 , 20 ( 1 ): 164 . DOI: 10.1186/s12943-021-01467-8 http://doi.org/10.1186/s12943-021-01467-8

PENG S , CHEN S L , HU W , et al . Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma [J ] . Cancer Immunol Res , 2022 , 10 ( 6 ): 728 - 744 . DOI: 10.1158/2326-6066.CIR-21-0931 http://doi.org/10.1158/2326-6066.CIR-21-0931 https://aacrjournals.org/cancerimmunolres/article/10/6/728/699035/Combination-Neoantigen-Based-Dendritic-Cell https://aacrjournals.org/cancerimmunolres/article/10/6/728/699035/Combination-Neoantigen-Based-Dendritic-Cell

LLOVET J M , MONTAL R , SIA D , et al . Molecular therapies and precision medicine for hepatocellular carcinoma [J ] . Nat Rev Clin Oncol , 2018 , 15 ( 10 ): 599 - 616 . DOI: 10.1038/s41571-018-0073-4 http://doi.org/10.1038/s41571-018-0073-4

ZHU A X , FINN R S , EDELINE J , et al . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial [J ] . Lancet Oncol , 2018 , 19 ( 7 ): 940 - 952 . DOI: S1470-2045(18)30351-6 http://doi.org/S1470-2045(18)30351-6

SHI J W , LIU J W , TU X X , et al . Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy [J ] . J Immunother Cancer , 2022 , 10 ( 1 ): e003133 . DOI: 10.1136/jitc-2021-003133 http://doi.org/10.1136/jitc-2021-003133 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-003133 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-003133

PINATO D J , MARRON T U , MISHRA-KALYANI P S , et al . Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice [J ] . Eur J Cancer , 2021 , 157 : 140 - 152 . DOI: 10.1016/j.ejca.2021.08.020 http://doi.org/10.1016/j.ejca.2021.08.020

WANG J , HUANG A , WANG Y P , et al . Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma [J ] . Ann Transl Med , 2020 , 8 ( 5 ): 237 . DOI: 10.21037/atm.2019.12.154 http://doi.org/10.21037/atm.2019.12.154

SUN Y F , WU L , LIU S P , et al . Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma [J ] . Nat Commun , 2021 , 12 ( 1 ): 4091 . DOI: 10.1038/s41467-021-24386-0 http://doi.org/10.1038/s41467-021-24386-0

RICCIUTI B , WANG X N , ALESSI J V , et al . Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels [J ] . JAMA Oncol , 2022 , 8 ( 8 ): 1160 - 1168 . DOI: 10.1001/jamaoncol.2022.1981 http://doi.org/10.1001/jamaoncol.2022.1981

LIN Z F , QIN L X , CHEN J H . Biomarkers for response to immunotherapy in hepatobiliary malignancies [J ] . Hepatobiliary Pancreat Dis Int , 2022 , 21 ( 5 ): 413 - 419 . DOI: 10.1016/j.hbpd.2022.08.002 http://doi.org/10.1016/j.hbpd.2022.08.002 https://linkinghub.elsevier.com/retrieve/pii/S1499387222001886 https://linkinghub.elsevier.com/retrieve/pii/S1499387222001886

LARKIN J , CHIARION-SILENI V , GONZALEZ R , et al . Five-year survival with combined nivolumab and ipilimumab in advanced melanoma [J ] . N Engl J Med , 2019 , 381 ( 16 ): 1535 - 1546 . DOI: 10.1056/NEJMoa1910836 http://doi.org/10.1056/NEJMoa1910836 http://www.nejm.org/doi/10.1056/NEJMoa1910836 http://www.nejm.org/doi/10.1056/NEJMoa1910836

Views

10477

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2024

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023

Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022

Advances in basic research, clinical diagnosis and treatment of prostate cancer in 2022

Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022

Related Author

Ting WANG

Yi QIN

Xiaowu XU

Xianjun YU

Tianjiao LI

Longyun YE

Kaizhou JIN

Weiding WU

Related Institution

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai Key Laboratory of Precision Medicine for Pancreatic Cancer, Pancreatic Cancer Institute, Fudan University

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute

Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute

AI问答

⁰